{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:26Z","timestamp":1791924206556,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.xkme.2021.08.008","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T18:25:29Z","timestamp":1634063129000},"page":"1074-1081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management"],"prefix":"10.1016","volume":"3","author":[{"given":"Harish","family":"Seethapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.xkme.2021.08.008_bib2","unstructured":"Timeline of progress. Cancer Research Institute. Accessed June 1, 2021. https:\/\/www.cancerresearch.org\/immunotherapy\/timeline-of-progress"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xkme.2021.08.008_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2021.08.008_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.xkme.2021.08.008_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2021.08.008_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib11","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Munoz","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.xkme.2021.08.008_bib12","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2021.08.008_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney International Reports"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.xkme.2021.08.008_bib16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","article-title":"Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort","volume":"36","author":"Stein","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.xkme.2021.08.008_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib18","first-page":"127","article-title":"Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity","volume":"44","author":"Sorah","year":"2021","journal-title":"J\u00a0Immunother"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2021.08.008_bib20","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.xkme.2021.08.008_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous Cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A\u00a0systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.xkme.2021.08.008_bib24","first-page":"190","article-title":"Immune checkpoint inhibitor therapy in patients with autoimmune disease","volume":"32","author":"Johnson","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib25","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.xkme.2021.08.008_bib26","first-page":"188","article-title":"Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul","year":"2016","journal-title":"J\u00a0Immunother"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/2399369321992776","article-title":"A\u00a0case of pembrolizumab induced distal renal tubular acidosis","volume":"5","author":"Atiq","year":"2021","journal-title":"Journal of Onco-Nephrology"},{"issue":"5","key":"10.1016\/j.xkme.2021.08.008_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-A report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"issue":"6","key":"10.1016\/j.xkme.2021.08.008_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1053\/j.ajkd.2016.06.009","article-title":"Cancer and mortality in solid-organ transplantation: preventable or inevitable?","volume":"68","author":"Asch","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.xkme.2021.08.008_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival after a cancer diagnosis among solid organ transplant recipients in the United States","volume":"125","author":"D'Arcy","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.xkme.2021.08.008_bib31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A\u00a0multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients","volume":"5","author":"Manohar","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"21","key":"10.1016\/j.xkme.2021.08.008_bib34","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.xkme.2021.08.008_bib36","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.xkme.2021.08.008_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.xkme.2021.08.008_bib38","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.xkme.2021.08.008_bib39","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.xkme.2021.08.008_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint - a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"17","key":"10.1016\/j.xkme.2021.08.008_bib43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.xkme.2021.08.008_bib45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2399369320945724","article-title":"Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography","volume":"4","author":"Heybeli","year":"2020","journal-title":"Journal of Onco-Nephrology"},{"issue":"8","key":"10.1016\/j.xkme.2021.08.008_bib48","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.xkme.2021.08.008_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J\u00a0Transl Med"},{"issue":"42","key":"10.1016\/j.xkme.2021.08.008_bib50","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.xkme.2021.08.008_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.xkme.2021.08.008_bib52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.21873\/anticanres.14063","article-title":"Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors","volume":"40","author":"Fiala","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.xkme.2021.08.008_bib54","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Accessed July 1, 2021. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib55","doi-asserted-by":"crossref","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib56","first-page":"156","article-title":"Mycophenolate as primary treatment for immune checkpoint inhibitor induced acute kidney injury in a patient with concurrent immunotherapy-associated diabetes: a case report","volume":"4","author":"Jessel","year":"2021","journal-title":"Clin Oncol Case Rep"},{"issue":"2","key":"10.1016\/j.xkme.2021.08.008_bib57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ccr3.3597","article-title":"Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer","volume":"9","author":"Omori","year":"2021","journal-title":"Clin Case Rep"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib58","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.xkme.2021.08.008_bib59","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.xkme.2021.08.008_bib60","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.xkme.2021.08.008_bib61","doi-asserted-by":"crossref","unstructured":"Chute DF, Zhao S, Strohbehn IA, et\u00a0al. Incidence and predictors of CKD and estimated gfr decline in patients receiving immune checkpoint inhibitors. Am J Kidney Dis. Published online June 24, 2021. https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.012","DOI":"10.1053\/j.ajkd.2021.05.012"},{"issue":"3","key":"10.1016\/j.xkme.2021.08.008_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.xkme.2021.08.008_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059521002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059521002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:22:00Z","timestamp":1762910520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059521002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2590059521002168"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2021.08.008","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2021.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}